NICE has issued a new draft version of its guidance on the clinical and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma. NICE has not yet issued final guidance to the NHS on the use of carmustine implants and temozolomide for this indication. Consultees, healthcare professionals and members of the public now have the opportunity to comment on the provisional recommendations contained in the draft document. All comments must be received by 31 January 2007. Final guidance is expected in June 2007.